Target Discovery and Validation Reviews and Protocols

114 Sørlie
62. Bergh, J., Norberg, T., Sjogren, S., Lindgren, A., and Holmberg, L. (1995)
Complete sequencing of the p53 gene provides prognostic information in breast
cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy.
Nat. Med. 1, 1029–1034.
63. Berns, E. M., Foekens, J. A., Vossen, R., et al. (2000) Complete sequencing of
TP53 predicts poor response to systemic therapy of advanced breast cancer.
Cancer Res. 60, 2155–2162.
64. Borresen, A. L., Andersen, T. I., Eyfjord, J. E., et al. (1995) TP53 mutations and
breast cancer prognosis: particularly poor survival rates for cases with mutations
in the zinc-binding domains. Genes Chromosomes Cancer 14, 71–75.
65. Sorlie, T., Johnsen, H., Vu, P., Lind, G. E., Lothe, R., and Borresen-Dale, A. L.
(2004) Mutation Screening of the TP53 Gene by Temporal Temperature Gradient
Gel Electrophoresis. Methods Mol. Biol. 291, 207–216.
66. Nakopoulou, L. L., Alexiadou, A., Theodoropoulos, G. E., Lazaris, A. C., Tzonou, A.,
and Keramopoulos, A. (1996) Prognostic significance of the co-expression of p53
and c-erbB-2 proteins in breast cancer. J. Pathol. 179, 31–38.
67. Sorlie, T. (2004) Molecular portraits of breast cancer: tumour subtypes as distinct
disease entities. Eur. J. Cancer 40, 2667–2675.
68. Pollack, J. R., Perou, C. M., Alizadeh, A. A., et al. (1999) Genome-wide analysis
of DNA copy-number changes using cDNA microarrays. Nat. Genet. 23, 41–46.
69. Pollack, J. R., Sorlie, T., Perou, C. M., et al. (2002) Microarray analysis reveals a
major direct role of DNA copy number alteration in the transcriptional program
of human breast tumors. Proc. Natl. Acad. Sci. USA 99, 12, 963–12, 968.
70. Forozan, F., Mahlamaki, E. H., Monni, O., et al. (2000) Comparative genomic
hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary
DNA microarray data. Cancer Res. 60, 4519–4525.
71. Kallioniemi, A., Kallioniemi, O. P., Piper, J., et al. (1994) Detection and mapping
of amplified DNA sequences in breast cancer by comparative genomic hybridization.
Proc. Natl. Acad. Sci. USA 91, 2156–2160.
72. Tirkkonen, M., Tanner, M., Karhu, R., Kallioniemi, A., Isola, J., and Kallioniemi,
O. P. (1998) Molecular cytogenetics of primary breast cancer by CGH. Genes
Chromosomes Cancer 21, 177–184.
73. Hyman, E., Kauraniemi, P., Hautaniemi, et al. (2002) Impact of DNA amplification
on gene expression patterns in breast cancer. Cancer Res. 62, 6240–6245.
74. Ramaswamy, S., Ross, K. N., Lander, E. S., and Golub, T., R. (2003) Amolecular
signature of metastasis in primary solid tumors. Nat. Genet. 33, 49–54.
75. Ein-Dor, L., Kela, I., Getz, G., Givol, D., and Domany, E. (2005) Outcome signature
genes in breast cancer: is there a unique set? Bioinformatics 21, 171–178.